Key facts
- It has raised $69.2M; the latest was Early Stage VC ($51.7M) in Sep 2024.
- Notable investors include CDP Venture Capital (Rome), Sofinnova Partners, Indaco Venture Partners, Large Ventures, XGEN Venture.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Genespire
- ·The full record, as it builds
Funding rounds
No funding rounds for Genespire are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Genespire
Developer of transformative gene therapies designed to treat patients affected by severe genetic diseases. The company's therapies combine integration-defective lentiviral vectors with gene editing for high efficacy and versatile targeted insertion of therapeutic genes in blood cells, enabling patients to have an arsenal of therapeutic alternatives adapted to each specific disease.
- Sector
- Healthcare
- HQ
- Milan, Italy
- Founded
- 2020
- Employees
- 10
- Website
- genespire.com/
- Ownership
- Privately Held (backing)
Genespire doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genespire shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genespire in its N-PORT filings yet. We sweep new filings monthly.